A five-year study has found something counterintuitive: people with obesity show lower Alzheimer's markers in their blood at the start, but then those markers rise dramatically faster over time. The research, presented at the Radiological Society of North America's annual meeting, tracked 407 participants using blood tests and brain imaging to understand how body weight influences the progression of Alzheimer's disease.
What the data revealed
Researchers analyzed blood samples and PET brain scans from participants in the Alzheimer's Disease Neuroimaging Initiative. They measured three key biomarkers: pTau217 (used to diagnose Alzheimer's), neurofilament light chain (a protein released when brain cells are damaged), and plasma GFAP (a protein that reflects stress in brain support cells). The pattern that emerged was striking. People with obesity experienced a 29% to 95% faster increase in pTau217 levels, a 24% faster rise in neurofilament light chain, and a 3.7% faster buildup of amyloid plaques in the brain itself.
The initial findings were puzzling. At baseline, people with obesity actually had lower biomarker levels in their blood—but not because they were healthier. "We believe the reduced biomarkers in obese individuals was due to dilution from higher blood volume," explained study lead author Soheil Mohammadi. In other words, the markers were there; they were just spread across a larger volume of blood. Without the five-year trajectory, researchers could have misread the data entirely.
We're a new kind of news feed.
Regular news is designed to drain you. We're a non-profit built to restore you. Every story we publish is scored for impact, progress, and hope.
Start Your News DetoxWhy this matters for prevention
Obesity is one of 14 modifiable risk factors linked to Alzheimer's disease. According to the 2024 Lancet Commission report, these factors account for roughly 45% of Alzheimer's risk. That means addressing weight—through lifestyle changes or medication—could meaningfully reduce disease risk or delay its onset.
Senior author Cyrus Raji noted the practical value: "The fact that we can track the predictive influence of obesity on rising blood biomarkers more sensitively than PET is what astonished me." Blood tests are cheaper, more accessible, and less invasive than brain imaging. If they can reliably predict disease progression, they become a powerful tool for monitoring how interventions work.
The research opens a specific door. New obesity medications have shown significant effects on weight loss. Future studies could measure whether these drugs also slow the rise in Alzheimer's biomarkers—essentially testing whether weight loss translates to brain protection. That kind of data would reshape how doctors approach prevention in midlife.
This work is foundational for the next phase: using blood biomarkers alongside brain imaging as standard practice to track treatment response, including anti-amyloid drugs. The timeline matters. If obesity accelerates pathology by decades, catching and reversing it earlier could shift the entire trajectory of disease.
